发明公开
- 专利标题: ORAL DOSAGE FORMS FOR MODIFIED RELEASE COMPRISING RUXOLITINIB
- 专利标题(中): 口服剂型与鲁索利替尼修饰释放
-
申请号: EP13740041.2申请日: 2013-07-25
-
公开(公告)号: EP2877162A1公开(公告)日: 2015-06-03
- 发明人: STEFAN, Ralph , SIEVERT, Frank , RIMKUS, Katrin
- 申请人: ratiopharm GmbH
- 申请人地址: Graf-Arco-Strasse 3 89079 Ulm DE
- 专利权人: ratiopharm GmbH
- 当前专利权人: ratiopharm GmbH
- 当前专利权人地址: Graf-Arco-Strasse 3 89079 Ulm DE
- 代理机构: Nachshen, Neil Jacob
- 优先权: EP12005485 20120727
- 国际公布: WO2014016396 20140130
- 主分类号: A61K9/20
- IPC分类号: A61K9/20 ; A61K9/48 ; A61K31/4045 ; A61K31/519
摘要:
The invention essentially relates to oral dosage forms comprising a JAK kinase inhibitor, preferably Ruxolitinib, suitable for modified release, and processes of preparing such oral dosage forms.
信息查询